IL5 and Alzheimer disease: Astegolimab, a fully human IgG2 monoclonal antibody that binds to ST2 (Figure 2b) and inhibits further signaling, given as 490 mg every 4 weeks for 16 weeks, was not able to demonstrate a significant difference compared with placebo for the primary outcome (change in EASI from baseline to week 16) and secondary outcomes (blood eosinophils, serum IL-5, and serum CCL13) in a phase 2 randomized clinical trial in 65 patients with AD by Maurer et al. [52].